Evidence map›Paper›PMID 32492907›Full record

ReviewJournal of clinical medicine2020

Diagnostic Biomarkers for Alzheimer's Disease Using Non-Invasive Specimens.

Maria Paraskevaidi, David Allsop, Salman Karim, Francis L Martin, StJohn Crean

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. An Update of Salivary Biomarkers for the Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Dysregulation ofCurrent Alzheimer research · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. A Novel Serum-Based Diagnosis of Alzheimer's Disease Using an Advanced Phage-Based Biochip.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Maria ParaskevaidiSchool of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK.
David AllsopDivision of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YW, UK.ORCID 0000-0002-0513-5575
Salman KarimCentral Lancashire Memory Assessment Service, Lancashire Care NHS Foundation Trust, Bamber Bridge, Preston PR5 6YA, UK.
Francis L MartinSchool of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK.ORCID 0000-0001-8562-4944
StJohn CreanSchool of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK.
University of Lancashire · GBLancashire Care NHS Foundation Trust · GBLancaster University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies in the field of Alzheimer's disease (AD) have shown the emergence of biomarkers in biologic fluids that hold great promise for the diagnosis of the disease. A diagnosis of AD at a presymptomatic or early stage may be the key for a successful treatment, with clinical trials currently investigating this. It is anticipated that preventative and therapeutic strategies may be stage-dependent, which means that they have a better chance of success at a very early stage-before critical neurons are lost. Several studies have been investigating the use of cerebrospinal fluid (CSF) and blood as clinical samples for the detection of AD with a number of established core markers, such as amyloid beta (Aβ), total tau (T-tau) and phosphorylated tau (

Indexed as

Alzheimer’s diseasebiomarkersbuccal cellsdiagnosticsearly detectionsalivary markers

Identifiers

PMID32492907
PMCPMC7356561
OpenAlexW3030856367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.